REG-Arix Bioscience PLC Arix to Present at Mello Investment Trusts & Funds

Arix BioscienceAnnouncement

06/12/2022 07:15

============

   Arix Bioscience PLC (ARIX)
   Arix to Present at Mello Investment Trusts & Funds

   06-Dec-2022 / 07:00 GMT/BST
   Dissemination of a Regulatory Announcement, transmitted by EQS Group.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

                                        

                              Arix Bioscience plc

                                        

               Arix to Present at Mello Investment Trusts & Funds

    

   LONDON, 6 December  2022: Arix  Bioscience plc (“Arix”  or the  “Company”)
   (LSE: ARIX),  a global  venture capital  company focused  on investing  in
   breakthrough biotechnology companies, announces  that the Company will  be
   presenting at the Mello Investment Trusts & Funds virtual webinar,  taking
   place between 2pm and 5pm on Tuesday 13 December 2022.

    

   Robert Lyne,  CEO, will  provide a  live  update and  Q&A session  on  the
   Company, its investment strategy and outlook, at 2.30pm on the day.

    

   The presentation will  be hosted online  and is open  to all existing  and
   potential shareholders. Individuals wishing to attend can register via the
   below link:

    

    1 https://melloevents.com/mello-investment-trusts-and-funds/

    

    

                                      ENDS 

    

   Enquiries

   For more information on Arix, please contact:

    

   Arix Bioscience plc

   +44 (0)20 7290 1050

   ir 2 @arixbioscience.com

    

   Powerscourt Group

   Sarah MacLeod, Ibrahim Khalil, Nick Johnson

   +44 (0)20 7250 1446

    3 arix@powerscourt-group.com

    

   About Arix Bioscience plc

   Arix Bioscience  plc  is  a  global venture  capital  company  focused  on
   investing in  breakthrough  biotechnology  companies  around  cutting-edge
   advances in life sciences.

    

   We collaborate  with exceptional  entrepreneurs and  provide the  capital,
   expertise, and  global  networks  to  help  accelerate  their  ideas  into
   important new treatments for patients. As a listed company, we are able to
   bring this exciting  growth phase of  our industry to  a broader range  of
   investors.  4 www.arixbioscience.com

    

    

   ══════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  MSCL
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   206324
   EQS News ID:    1505503


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    5 fncls.ssp?fn=show_t_gif&application_id=1505503&application_name=news&site_id=refinitiv

References

   Visible links
   1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=3c27ad3b73b9edc52f19e202b608f7ea&application_id=1505503&site_id=refinitiv&application_name=news
   2. mailto:charlotte@arixbioscience.com
   3. mailto:arix@powerscourt-group.com
   4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1505503&site_id=refinitiv&application_name=news


============